Compare Amgen, Inc. (AMGN) vs Constellation Energy Corporation (CEG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Constellation Energy Corporation — how do they compare? Amgen, Inc. trades at $356.86 (market cap $196.12B), while Constellation Energy Corporation trades at $255.39 (market cap $89.77B). The key difference: Amgen, Inc. is far larger — about 2.2× Constellation Energy Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | CEG | |
|---|---|---|
Market Cap | $196.12B | $89.77B |
Sector | Health | Energy |
52-Week High | $388.16 | $403.95 |
52-Week Low | $271.18 | $236.50 |
Enterprise Value | $241.41B | $111.43B |
Dividend Yield | 2.77% | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Constellation Energy (CEG) trades at $251.38, up 0.26% with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with 12.69% net margin and 16.33% ROE, supported by positive earnings beats in recent quarters. Analyst consensus remains strongly bullish with a $343.50 price target, representing 37% upside potential. Recent news highlights CEG's strategic positioning to benefit from AI-driven electricity demand and nuclear power resurgence.
CEG offers compelling growth exposure to clean energy transition with nuclear power advantages, though technical weakness and significant capital expenditures pose near-term challenges. The company's long-term power purchase agreements with major corporations provide revenue visibility, while valuation multiples remain reasonable relative to growth prospects. Execution on capital projects and regulatory developments represent key monitoring points for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →
